JP2006519814A5 - - Google Patents

Download PDF

Info

Publication number
JP2006519814A5
JP2006519814A5 JP2006504813A JP2006504813A JP2006519814A5 JP 2006519814 A5 JP2006519814 A5 JP 2006519814A5 JP 2006504813 A JP2006504813 A JP 2006504813A JP 2006504813 A JP2006504813 A JP 2006504813A JP 2006519814 A5 JP2006519814 A5 JP 2006519814A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
disease
compound
prophylactic
therapeutic treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2006504813A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006519814A (ja
JP4639182B2 (ja
Filing date
Publication date
Priority claimed from EP03290569A external-priority patent/EP1454909B1/en
Application filed filed Critical
Publication of JP2006519814A publication Critical patent/JP2006519814A/ja
Publication of JP2006519814A5 publication Critical patent/JP2006519814A5/ja
Application granted granted Critical
Publication of JP4639182B2 publication Critical patent/JP4639182B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2006504813A 2003-03-07 2004-03-05 置換された8’−ピリジニル−ジヒドロスピロ−[シクロアルキル]−ピリミド[1,2−a]ピリミジン−6−オンおよび8’−ピリミジニル−ジヒドロスピロ−[シクロアルキル]−ピリミド[1,2−a]ピリミジン−6−オン誘導体 Expired - Fee Related JP4639182B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03290569A EP1454909B1 (en) 2003-03-07 2003-03-07 8'-pyridinyl-dihydrospiro- (cycloalkyl) -pyrimido (1,2-a) pyrimidin-6-one and 8'-pyrimidinyl-dihydrospiro (cycloalkyl) -pyrimido (1,2-a) pyrimidin-6-one derivatives and their use against neurodegenerative diseases
PCT/EP2004/003051 WO2004078760A1 (en) 2003-03-07 2004-03-05 SUBSTITUTED 8'-PYRIDINYL-DIHYDROSPIRO-[CYCLOALKYL]-PYRIMIDO [1,2-a] PYRIMIDIN-6-ONE AND 8'-PYRIMIDINYL-DIHYDROSPIRO-[CYCLOALKYL]-PYRIMIDO [1,2-a] PYRIMIDIN-6-ONE DERIVATIVES AND THEIR USE AGAINST NEUROGENERATIVE DISEASES

Publications (3)

Publication Number Publication Date
JP2006519814A JP2006519814A (ja) 2006-08-31
JP2006519814A5 true JP2006519814A5 (https=) 2007-04-19
JP4639182B2 JP4639182B2 (ja) 2011-02-23

Family

ID=32799103

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006504813A Expired - Fee Related JP4639182B2 (ja) 2003-03-07 2004-03-05 置換された8’−ピリジニル−ジヒドロスピロ−[シクロアルキル]−ピリミド[1,2−a]ピリミジン−6−オンおよび8’−ピリミジニル−ジヒドロスピロ−[シクロアルキル]−ピリミド[1,2−a]ピリミジン−6−オン誘導体

Country Status (25)

Country Link
US (2) US7294632B2 (https=)
EP (2) EP1454909B1 (https=)
JP (1) JP4639182B2 (https=)
KR (1) KR101069984B1 (https=)
CN (1) CN100463908C (https=)
AR (1) AR043485A1 (https=)
AT (1) ATE469153T1 (https=)
AU (1) AU2004218250B2 (https=)
BR (1) BRPI0408189A (https=)
CA (1) CA2516937C (https=)
CY (1) CY1111057T1 (https=)
DE (1) DE602004027354D1 (https=)
DK (1) DK1603915T3 (https=)
EA (1) EA008172B1 (https=)
ES (1) ES2346311T3 (https=)
IL (1) IL170461A (https=)
MX (1) MXPA05009574A (https=)
NO (1) NO20054140L (https=)
NZ (1) NZ542135A (https=)
PL (1) PL1603915T3 (https=)
PT (1) PT1603915E (https=)
SI (1) SI1603915T1 (https=)
TW (1) TWI320785B (https=)
WO (1) WO2004078760A1 (https=)
ZA (1) ZA200507107B (https=)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080025079A (ko) 2005-06-14 2008-03-19 쉐링 코포레이션 아스파르틸 프로테아제 억제제
EP2275095A3 (en) 2005-08-26 2011-08-17 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP2258358A3 (en) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
EP1940389A2 (en) 2005-10-21 2008-07-09 Braincells, Inc. Modulation of neurogenesis by pde inhibition
AU2006308889A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. GABA receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
EP2382975A3 (en) 2006-05-09 2012-02-29 Braincells, Inc. Neurogenesis by modulating angiotensin
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
EP1992624A1 (en) 2007-05-16 2008-11-19 Sanofi-Aventis Heteroarylamide pyrimidone compounds
EP1992625A1 (en) * 2007-05-16 2008-11-19 Sanofi-Aventis Arylamide pyrimidone compounds
EP1992621A1 (en) 2007-05-16 2008-11-19 Sanofi-Aventis Heteroarylamide-substituted pyrimidone derivatives for the treatment of neurodegenerative diseases
EP1992620A1 (en) * 2007-05-16 2008-11-19 Sanofi-Aventis Arylamide pyrimidone derivatives for the treatment of neurodegenerative diseases
EP2138498A1 (en) 2008-06-26 2009-12-30 sanofi-aventis Substituted tricyclic derivatives against neurodegenerative diseases
EP2138488A1 (en) 2008-06-26 2009-12-30 sanofi-aventis 4-(pyridin-4-yl)-1H-[1,3,5]triazin-2-one derivatives as GSK3-beta inhibitors for the treatment of neurodegenerative diseases
EP2138485A1 (en) 2008-06-26 2009-12-30 sanofi-aventis Substituted N-Oxide pyrazine derivatives
EP2138495A1 (en) * 2008-06-26 2009-12-30 sanofi-aventis Substituted pyrimido[2,1-a]isoquinolin-4-one derivatives
EP2138494A1 (en) 2008-06-26 2009-12-30 Sanofi-Aventis Substituted alkyl pyrimidin-4-one derivatives
EP2138492A1 (en) 2008-06-26 2009-12-30 Sanofi-Aventis Substituted pyrimidin-4-one derivatives
EP2138493A1 (en) 2008-06-26 2009-12-30 Sanofi-Aventis Substituted pyrimidone derivatives
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
CN102482286B (zh) 2009-07-02 2015-07-15 赛诺菲 新型1,2,3,4-四氢嘧啶并{1,2-a}嘧啶-6-酮衍生物、其制备以及其医药用途
DK2655375T3 (en) 2010-12-23 2015-03-09 Sanofi Sa PYRIMIDINON DERIVATIVES, PREPARATION AND PHARMACEUTICAL USE THEREOF
FR2992316A1 (fr) 2012-06-22 2013-12-27 Sanofi Sa Derives de pyrimidinones, leur preparation et leur application en therapeutique
FR2992314B1 (fr) 2012-06-22 2015-10-16 Sanofi Sa Nouveaux derives de 2,3-dihydro-1h-imidazo{1,2-a}pyrimidin-5-one et 1,2,3,4-tetrahydro-pyrimido{1,2-a}pyrimidin-6-one comportant une morpholine substituee, leur preparation et leur utilisation pharmaceutique
CA2945263A1 (en) 2014-04-09 2015-10-15 Christopher Rudd Use of gsk-3 inhibitors or activators which modulate pd-1 or t-bet expression to modulate t cell immunity

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2812636A1 (fr) * 2000-08-02 2002-02-08 Novapharme Nouveaux derives 2-phenyl imidazo[1.2-a]pyrimidin-5-ones et 2-phenyl 2,3-dihydro imidazo[1,2-a]pyrimidin-5-ones
EP1184383A1 (en) * 2000-09-01 2002-03-06 Sanofi-Synthelabo 9-[Alkyl], 9-[(heteroaryl)alkyl] and 9-[(aryl)alkyl]-2-pyridinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one derivatives
EP1184385A1 (en) * 2000-09-01 2002-03-06 Sanofi-Synthelabo 1-[Alkyl], 1-[(heteroaryl)alkyl] and 1-[(aryl)alkyl]-7-pyridin-4-yl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1H)-one derivatives
AR030587A1 (es) * 2000-09-01 2003-08-27 Sanofi Aventis Derivados de 2-piridinil-6,7,8,9-tetrahidropirimido[1,2-a]pirimidin-4-ona y 7-piridinil-2,3-dihidroimidazo[1,2-a]pirimidin-5(1h)-ona
CA2457965C (en) * 2001-09-21 2010-06-01 Sanofi-Synthelabo Substituted 2-pyridinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one and 7-pyridinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1h)one derivatives
EA007165B1 (ru) * 2001-09-21 2006-08-25 Санофи-Авентис Производные замещенного 2-пиримидинил-6, 7, 8, 9-тетрагидропиримидо [1,2-а]пиримидин-4-она и 7-пиримидинил-2,3-дигидроимидазо[1, 2-а]пиримидин-5( 1н )она для нейродегенеративных нарушений
EP1295884A1 (en) * 2001-09-21 2003-03-26 Sanofi-Synthelabo 2-pyrimidinyl-6,7,8,9-tetrahydropyrimido[1,2-a]Pyrimidin-4-one and 7-Pyrimidinyl-2,3-Dihydroimidazo[1,2-a]Pyrimidin-5(1H)one derivatives
EP1295885A1 (en) * 2001-09-21 2003-03-26 Sanofi-Synthelabo Substituted 2-pyridinyl-6,7,8,9-tetrahydropyrimido(1,2-a)pyrimidin-4-one and 7-pyridinyl-2,3-dihydroimidazo(1,2-a)pyrimidin-5(1H)one derivatives

Similar Documents

Publication Publication Date Title
JP2006519814A5 (https=)
JP2006520766A5 (https=)
CN101861316B (zh) 咪唑并[1,2-a]吡啶衍生物及其作为MGLUR2受体的正变构调节剂的用途
CA2836410C (en) Tyrosine kinase inhibitors
CN103298809B (zh) 1,2,4-三唑并[4,3-a]吡啶衍生物及其作为MGLUR2受体的正变构调节剂的用途
CN109863152B (zh) 3-苯基-2,3,4,8,9,10-六氢吡喃并[2,3-f]色烯衍生物以及用于合成其光学异构体的方法
CN106456643B (zh) 用于trail诱导的药效团
JP2019528276A5 (https=)
CA2562859A1 (en) Novel enantiomerically pure beta-agonists, method for the production and the use thereof in the form of a drug
EP2360165A3 (de) Glucopyranosyl-substituierte Benzol-Derivate, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
NZ592723A (en) Cyclic pyrimidin-4-carboxamides as ccr2 receptor antagonists for treatment of inflammation, asthma and copd
CN1575287A (zh) 乙酰替苯胺衍生物的α型或β型结晶
JP2011510972A5 (https=)
HUE031248T2 (en) New bicyclic pyridinones
MX2007003031A (es) Compuestos heteroarilo para uso como betamimeticos en el tratamiento de enfermedades de vias respiratorias.
CN102503842B (zh) 一种姜黄素衍生物及其制备方法和用途
CN114364685A (zh) 含氮杂环类化合物,及其制备方法、药物组合物和应用
JP6332818B2 (ja) チカグレロルの中間体およびその製造法、およびチカグレロルの製造法
NL1029919C2 (nl) Therapeutische difenyletherliganden.
CN1319976C (zh) 化学中间体
TW200716152A (en) Substituted 1,2-ethylendiamines, medicaments comprising said compound, their use and their method of manufacture
CN108689982B (zh) 一种具有α,β-不饱和酮结构片段的香豆素衍生物及其制备方法和用途
MX2009010243A (es) Compuestos de quinolina apropiados para tratar trastornos que responden a la modulacion del receptor de serotonina 5-ht6.
JP2006519813A5 (https=)
JP5065020B2 (ja) レボフロキサシンまたはその水和物の製造方法